Ann: Quarterly Results and Investor Conference Call Notification, page-37

I refer back to the 25th August Ann on growth:

"Under the contract with GE Healthcare, there are prescribed minimum order quantities increasing each year with further
upside when sales exceed these quantities. This milestone agreement is expected to contribute materially to Osprey’s
revenue over the 4-year contracted period. This agreement represents a significant shift for the company and means that
OUS sales will now contribute materially to Osprey’s group revenues and complement the existing growth of sales
generated within the US."

"As previously communicated, based on conservative estimates, the distribution agreement is expected to add +20% to
Osprey’s total expected revenues in 2021 with this expected to scale in importance each year, reaching +40% by the
fourth year. Additionally, all transfer prices have been set over the 4-year period whereby Osprey will experience an
average gross margin of ~50% furthering margin certainty across the business from a pricing perspective."

"DyeVert™ unit sales of 3,250 in 1H 2020, a 40% reduction compared to 1H 2019 due to COVID-19 disruptions"